Exisulind
Exisulind
Exisulind (pronounced ex-i-sul-ind) is a pharmaceutical drug that was initially developed for the treatment of colorectal cancer. It is a derivative of sulindac, a non-steroidal anti-inflammatory drug (NSAID).
Etymology
The name "Exisulind" is derived from its parent compound, sulindac. The prefix "Exi-" is a common pharmaceutical prefix, often used to denote a derivative or variant of a parent compound.
Pharmacology
Exisulind works by inducing apoptosis, or programmed cell death, in cancer cells. It does this by inhibiting cyclic GMP phosphodiesterase, an enzyme that is often overexpressed in cancer cells. This inhibition leads to an increase in cyclic GMP, which in turn activates protein kinase G, leading to apoptosis.
Clinical Use
Exisulind has been studied for use in a variety of cancers, including colorectal cancer, prostate cancer, and lung cancer. However, it has not been approved by the Food and Drug Administration (FDA) for any indication.
Related Terms
- Sulindac: The parent compound of exisulind.
- Apoptosis: The process of programmed cell death that exisulind induces in cancer cells.
- Cyclic GMP phosphodiesterase: The enzyme that exisulind inhibits to induce apoptosis.
- Protein kinase G: The protein that is activated by the increase in cyclic GMP caused by exisulind.
External links
- Medical encyclopedia article on Exisulind
- Wikipedia's article - Exisulind
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski